Pipeline

Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) ranked as the 5th to 9th most common cancer in most countries worldwide, with almost 510,000 new cases estimated in 2018.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL (~30%). HemaMax combine with second line Standard of Care is ongoing.

Cutaneous T Cell Lymphoma (CTCL) is a rare skin-trafficking malignant CD4 T-helper lymphocytes with a incidence rate 11.32 cases per million. HemaMax combine with low-dose total skin electron beam therapy in Phase 2 study shows a better outcome. EOP2 meeting with the FDA held in May 2018, where protocol and SAP were acceptable to the FDA in an accelerated approval pathway.
Medical Countermeasures
Medical countermeasures (MCMs) are medicines and medical supplies that can be used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear (CBRN) threats. Single dose HemaMax, survival benefit shown in all studies without supportive care (NO fluids, antibiotics or blood products)
Immuno Checkpoint Blockade Combination Therapy
Immuno Checkpoint Blockade have revolutionized the treatment of a variety of malignancies, and the global market is expected to grow from $15.29 billion in 2020 to $18.04 billion in 2021 at a compound annual growth rate (CAGR) of 18%.

But significant durable responses only occur in a small percentage of patients, and other patients failed to respond to the treatment. It is noteworthy that novel therapeutic approaches based on the efficient combination of HemaMax with the PD‐L1/PD‐1 blockade therapy can enhance antitumor immune responses against various malignancies.